Sabby Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Sabby Management’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-93,295	Closed	-$830K	–	154
2018 Q2	$830K	Buy	93,295 +1,310	+1%	+$11.6K	0.13%	68
2018 Q1	$812K	Sell	91,985 -39,944	-30%	-$411K	0.1%	78
2017 Q4	$1.35M	Buy	+131,929	New	+$1.59M	0.12%	61
2017 Q3	–	Sell	-52,982	Closed	-$476K	–	233
2017 Q2	$476K	Buy	+52,982	New	+$1.04M	0.03%	141

Other funds holding IDXG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Sabby Management's IDXG Position: Q3 2018 in Review

Sabby Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2018, closing a stake of 93,295 shares — an estimated $830K sold.

Sabby Management first reported a position in IDXG in Q2 2017 and held it in 4 quarters. The position peaked at $1.35M in Q4 2017. 18 funds tracked by Wall St. Rank hold IDXG as of Q3 2018.

Sabby Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Sabby Management sold 93,295 Interpace Biosciences, Inc. Common Stock shares in Q3 2018, an estimated $830K.
Sabby Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
Sabby Management's Interpace Biosciences, Inc. Common Stock position peaked at $1.35M in Q4 2017.
18 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2018.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.